Clinical Trials · NCT05774756
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 143
- Start date
- Apr 2023
- Locations
- 28 sites, 6 countries
- Primary endpoint
- Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen